Activity Description & Educational Objectives
In this activity, a panel of experts on bipolar disorder discusses the clinical challenges associated with diagnosing and treating bipolar depression. Topics covered include strategies for the timely identification of bipolar disorder, obstacles to diagnosis and effective treatment of bipolar depression, and recent efficacy and safety data on therapeutic options for these patients.
Upon completion of this activity, participants should be better able to:
- Identify the current challenges associated with the diagnosis and management of bipolar depression
- Develop strategies to facilitate the timely identification of patients with bipolar depression through the application of a comprehensive evaluation as well as validated screening tools and severity scales
- Evaluate current efficacy and safety data related to the various therapeutic options for bipolar depression
This activity has been designed to meet the educational needs of psychiatrists and other clinicians involved in the care of patients with bipolar disorder.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: December 11, 2012 - December 10, 2013
Time to Complete: 45 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Moderator
Gary S. Sachs, MD
Associate Professor of Psychiatry
Harvard Medical School
Founding Director, Bipolar Clinic and Research Program
Massachusetts General Hospital
Gary S. Sachs, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Forest Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Otsuka Pharmaceutical Co., Ltd.; and Sunovion Pharmaceuticals Inc.
Other Financial or Material Support from Bracket in the form of employment affiliation.
Mark A. Frye, MD
Chair, Department of Psychiatry and Psychology
Professor of Psychiatry
Director, Mayo Clinic Depression Center
Department of Psychiatry & Psychology
Mark A. Frye, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Mayo Foundation for Medical Education and Research; Myriad RBM; National Institute on Alcohol Abuse and Alcoholism; Pfizer Inc.; The Brain & Behavior Research Foundation formerly known as the National Alliance for Research on Schizophrenia and Depression (NARSD); and The National Institute of Mental Health.
Other Financial or Material Support from AstraZeneca; Bristol-Myers Squibb Company; GlaxoSmithKline; and sanofi-aventis in the form of CME travel support.
Terence A. Ketter, MD
Chief, Bipolar Disorders Clinic
Associate Director, Stanford University Mood Disorders Center
Department of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
Terence A. Ketter, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Allergan, Inc.; Avanir Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; and Teva Pharmaceuticals (Cephalon, Inc.).
Grant/Research Support from Agency for Healthcare Research and Quality; AstraZeneca; Eli Lilly and Company; Pfizer Inc.; Sunovion Pharmaceuticals Inc.; and Teva Pharmaceuticals (Cephalon, Inc.).
Honoraria from Abbott Laboratories; GlaxoSmithKline; and Otsuka Pharmaceutical Co., Ltd. in the form of lectures.
Other Financial or Material Support from American Psychiatric Publishing in the form of royalties. Spouse is an employee and has stock in Janssen Pharmaceuticals, Inc.
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education
Kirk A. Tacka, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5207-13-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.